Over at In the Pipeline, Derek Lowe comments on the fact that slowly but surely, Merck has been getting many of the large Vioxx judgments against it overturned on appeal. Out of 20 that went to court, Merck has won 17. Part of the problem, says Lowe, is that the bad effects (heart attacks) happened to only a few people, compared to the total number who were taking the drug, many of whom didn't need it.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.